指南与共识泌尿与男性生殖病理细胞病理与分子病理

2019年GUPS前列腺癌分级白皮书

The 2019 Genitourinary Pathology Society (GUPS) White Paper on Contemporary Grading of Prostate Cancer.
指南 / 共识 · Arch Pathol Lab Med · 2021-01-01

2019年泌尿生殖病理学会(GUPS)发布白皮书,通过文献综述和病理/临床调查更新前列腺癌分级建议,涵盖%GP4报告、 tertiary pattern、MRI靶向活检评分、GrGp术语、筛状癌和导管内癌报告、分子检测及人工智能应用等。

要点

  • 报告%GP4:穿刺活检GrGp2/3及部分GS4+4=8病例报告,分<5%、<10%和10%递增。
  • 根治标本GrGp2/3且GP5<5%时使用minor TP5,GS和GrGp基于原GS。
  • 报告筛状癌和IDC-P,IDC-P不纳入最终GS/GrGp,必要时用基底细胞免疫染色。

核心结论

  • 更新前列腺癌分级推荐,涵盖%GP4、三级模式、MRI靶向活检、GrGp、筛状癌、IDC-P、分子检测和人工智能等。

研究设计与样本

  • 基于文献批判性综述以及病理学家和临床医生调查的共识声明。

主要发现

  • 穿刺活检GrGp2和3应报告%GP4,GrGp2和3且<5% GP5时报告minor TP5。
  • 多针MRI靶向 lesion 作为一个整体评分,全局评分整合系统和靶向结果。
  • 筛状癌和IDC-P在活检和根治标本中报告,IDC-P不纳入最终GS/GrGp。

关键数值与推荐

  • 报告%GP4分<5%或<10%及之后10%递增;minor TP5仅用于RP GrGp2/3且GP5<5%。
  • IDC-P诊断标准:密集筛状腺体(>50%上皮)、实性巢和/或显著异型性/坏死。
  • 保留GS 3+5=8在GrGp4;Ki67不常规临床使用,PTEN和RNA检测需进一步研究。

临床怎么用

  • 按推荐报告%GP4、minor TP5、筛状癌和IDC-P,使用GrGp术语。
  • MRI靶向活检多针未指定时给整体评分,提供全局评分时整合系统和靶向结果。
  • IDC-P不纳入最终GS/GrGp,必要时用基底细胞免疫染色鉴别。

局限性

  • 基于文献综述和调查的共识,部分建议证据级别未明确。
  • 分子检测和人工智能应用尚未成熟,需进一步研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT.—: Controversies and uncertainty persist in prostate cancer grading. OBJECTIVE.—: To update grading recommendations. DATA SOURCES.—: Critical review of the literature along with pathology and clinician surveys. CONCLUSIONS.—: Percent Gleason pattern 4 (%GP4) is as follows: (1) report %GP4 in needle biopsy with Grade Groups (GrGp) 2 and 3, and in needle biopsy on other parts (jars) of lower grade in cases with at least 1 part showing Gleason score (GS) 4 + 4 = 8; and (2) report %GP4: less than 5% or less than 10% and 10% increments thereafter. Tertiary grade patterns are as follows: (1) replace "tertiary grade pattern" in radical prostatectomy (RP) with "minor tertiary pattern 5 (TP5)," and only use in RP with GrGp 2 or 3 with less than 5% Gleason pattern 5; and (2) minor TP5 is noted along with the GS, with the GrGp based on the GS. Global score and magnetic resonance imaging (MRI)-targeted biopsies are as follows: (1) when multiple undesignated cores are taken from a single MRI-targeted lesion, an overall grade for that lesion is given as if all the involved cores were one long core; and (2) if providing a global score, when different scores are found in the standard and the MRI-targeted biopsy, give a single global score (factoring both the systematic standard and the MRI-targeted positive cores). Grade Groups are as follows: (1) Grade Groups (GrGp) is the terminology adopted by major world organizations; and (2) retain GS 3 + 5 = 8 in GrGp 4. Cribriform carcinoma is as follows: (1) report the presence or absence of cribriform glands in biopsy and RP with Gleason pattern 4 carcinoma. Intraductal carcinoma (IDC-P) is as follows: (1) report IDC-P in biopsy and RP; (2) use criteria based on dense cribriform glands (>50% of the gland is composed of epithelium relative to luminal spaces) and/or solid nests and/or marked pleomorphism/necrosis; (3) it is not necessary to perform basal cell immunostains on biopsy and RP to identify IDC-P if the results would not change the overall (highest) GS/GrGp part per case; (4) do not include IDC-P in determining the final GS/GrGp on biopsy and/or RP; and (5) "atypical intraductal proliferation (AIP)" is preferred for an intraductal proliferation of prostatic secretory cells which shows a greater degree of architectural complexity and/or cytological atypia than typical high-grade prostatic intraepithelial neoplasia, yet falling short of the strict diagnostic threshold for IDC-P. Molecular testing is as follows: (1) Ki67 is not ready for routine clinical use; (2) additional studies of active surveillance cohorts are needed to establish the utility of PTEN in this setting; and (3) dedicated studies of RNA-based assays in active surveillance populations are needed to substantiate the utility of these expensive tests in this setting. Artificial intelligence and novel grading schema are as follows: (1) incorporating reactive stromal grade, percent GP4, minor tertiary GP5, and cribriform/intraductal carcinoma are not ready for adoption in current practice.

来源:Arch Pathol Lab Med,查看原文。版权归原作者所有。

引用

  1. Epstein JI, Amin MB, Fine SW, et al. The 2019 Genitourinary Pathology Society (GUPS) White Paper on Contemporary Grading of Prostate Cancer. Arch Pathol Lab Med. 2021. PMID: 32589068. doi:10.5858/arpa.2020-0015-RA

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。